Konrad Bork

ORCID: 0000-0002-6084-4577 · 3 papers in corpus
guideline 2025
Hereditary Angioedema with Normal C1 Inhibitor: an Updated International Consensus Paper on Diagnosis, Pathophysiology, and Treatment
Clinical reviews in allergy & immunology ·doi:10.1007/s12016-025-09027-4

Hereditary angioedema (HAE) has been recognized for almost 150 years. The newest form of HAE, where C1 inhibitor levels are normal (HAE-nC1INH), was first described in 2000. Over the last two decades, new types of apparent non-mast cell-med…

observational 2008
Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients
Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology ·doi:10.1016/s1081-1206(10)60424-3

BACKGROUND: Hereditary angioedema (HAE) due to C1 inhibitor deficiency is clinically characterized by relapsing skin swellings, abdominal pain attacks, and life-threatening upper airway obstruction. Treatment with androgens prevents attacks…

other 2004
Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond
The Journal of allergy and clinical immunology ·doi:10.1016/j.jaci.2004.06.047

Hereditary angioedema (HAE), a rare but life-threatening condition, manifests as acute attacks of facial, laryngeal, genital, or peripheral swelling or abdominal pain secondary to intra-abdominal edema. Resulting from mutations affecting C1…